Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study

被引：0
|
作者：
Wu, L. [1 ]
Hu, C. [2 ]
Su, W. [3 ]
Yu, Y. [4 ]
Hong, W. [5 ]
Liu, Z. [6 ,8 ]
Su, H. [7 ]
Liu, Z. [6 ,8 ]
Wang, C. [9 ]
Pu, Q. [10 ]
Guo, H. [11 ]
Min, X. [12 ]
Chen, Y. [3 ]
Zhu, H. [13 ]
Luo, T. [14 ]
机构：
[1] Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp, Shanxi Hosp, Taiyuan, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Univ Chinese Acad Sci, Dept Chest Oncol, Canc Hosp, Beijing, Peoples R China
[6] Southern Med Univ, Affiliated Hosp 10, Dongguan Peoples Hosp, Dongguan, Peoples R China
[7] Air Force Med Univ, Xian, Peoples R China
[8] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[9] Shandong First Med Univ, Shandong Prov Hosp, Jinan, Shandong, Peoples R China
[10] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
[12] AN HUI CHEST Hosp, Hefei, Anhui, Peoples R China
[13] Shandong First Med Univ, Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[14] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Extensive-stage small cell lung cancer; PD-1; inhibitor; Serplulimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.07
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [1] Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.
    Wu, Lin
    Hu, ChengPing
    Su, Wenzhong
    Yu, Yan
    Hong, Wei
    Liu, Zhigang
    Su, Haichuan
    Liu, Zhentian
    Wang, Caixia
    Pu, Qing
    Guo, Hui, Sr.
    Min, Xuhong
    Chen, Yifei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)
    Cheng, Y.
    Han, L.
    Wu, L.
    Chen, J.
    Sun, H.
    Wen, G.
    Ji, Y.
    Dvorkin, M.
    Shi, J.
    Pan, Z.
    Shi, J.
    Wang, X.
    Bai, Y.
    Melkadze, T.
    Pan, Y.
    Min, X.
    Viguro, M.
    Kang, W.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1562 - S1562
  • [3] Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Dvorkin, Mikhail
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Bai, Yuansong
    Melkadze, Tamar
    Pan, Yueyin
    Min, Xuhong
    Viguro, Maksym
    Li, Xingya
    Zhao, Yanqiu
    Yang, Junquan
    Makharadze, Tamta
    Arkania, Ekaterine
    Kang, Wenying
    Wang, Qingyu
    Zhu, Jun
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12): : 1223 - 1232
  • [4] First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM 004R study
    Shen, B.
    Yu, Z.
    Ding, H.
    Wang, H.
    Li, J.
    Xu, X.
    Tian, G.
    Han, G.
    Yin, L.
    Ji, Y.
    Zhou, Z.
    Zhou, L.
    Zhang, X.
    Sun, C.
    Ding, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1660 - S1660
  • [5] The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
    Choi, Myeong Geun
    Kim, Yeon Joo
    Lee, Jae Cheol
    Ji, Wonjun
    Oh, In -Jae
    Lee, Sung Yong
    Yoon, Seong Noon
    Lee, Shin Yup
    Lee, Jeong Eun
    Kim, Eun Young
    Choi, Chang-Min
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 422 - 429
  • [6] Immunotherapy retreatment with serplulimab versus chemotherapy in extensive-stage advanced small cell lung cancer previously treated with first-line immunotherapy: A real-world retrospective cohort study
    Liu, C.
    Wu, X.
    Zheng, C.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1072 - S1072
  • [7] Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
    Xiang, Guiyuan
    Jiang, Tingting
    Gan, Lanlan
    Wu, Yuanlin
    Zhang, Ni
    Xing, Haiyan
    Su, Hui
    Li, Yanping
    Peng, Dan
    Ni, Rui
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
    Takeda, Takayuki
    Yamada, Tadaaki
    Kunimatsu, Yusuke
    Tanimura, Keiko
    Morimoto, Kenji
    Shiotsu, Shinsuke
    Chihara, Yusuke
    Okada, Asuka
    Horiuchi, Shigeto
    Hibino, Makoto
    Uryu, Kiyoaki
    Honda, Ryoichi
    Yamanaka, Yuta
    Yoshioka, Hiroshige
    Kurata, Takayasu
    Takayama, Koichi
    CANCERS, 2023, 15 (05)
  • [9] The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
    Zheng, Hao-Ran
    Jiang, Ai-Min
    Gao, Huan
    Liu, Na
    Zheng, Xiao-Qiang
    Fu, Xiao
    Zhang, Rui
    Ruan, Zhi-Ping
    Tian, Tao
    Liang, Xuan
    Yao, Yu
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2273 - 2287
  • [10] Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
    Kim, Soo Han
    Jo, Eun Jung
    Mok, Jeongha
    Lee, Kwangha
    Kim, Ki Uk
    Park, Hye-Kyung
    Lee, Min Ki
    Eom, Jung Seop
    Kim, Mi-Hyun
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (02): : 218 - 225
12345